Get the Stockscreener App
5.54
3.55%
0.19
Rezolute Inc stock is traded at $5.54, with a volume of 919.68K.
It is up +3.55% in the last 24 hours and up +34.14% over the past month.
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
See More
Previous Close:
$5.35
Open:
$5.35
24h Volume:
919.68K
Relative Volume:
0.72
Market Cap:
$473.78M
Revenue:
-
Net Income/Loss:
$-69.31M
P/E Ratio:
-4.3622
EPS:
-1.27
Net Cash Flow:
$-62.80M
1W Performance:
+5.52%
1M Performance:
+34.14%
6M Performance:
+13.76%
1Y Performance:
+19.40%
1-Day Range:
$5.325
$5.62
1-Week Range:
$5.07
$5.62
52-Week Range:
$2.215
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
5.54 | 455.78M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Why Rezolute Inc. stock attracts strong analyst attentionInstant Stock Updates - Newser
What makes Rezolute Inc. stock price move sharplyFree Best Performing Stock Alerts - Newser
How Rezolute Inc. stock performs during market volatilityFree Trading Strategy Suggestions - Newser
Rezolute Announces Presentation of Participant Baseline Data From Its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - 富途牛牛
Rezolute, Inc. Announces Late-Breaking Presentation of Phase 3 Study Data for Ersodetug at ENDO 2025 - Quiver Quantitative
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) - TradingView
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional investors must be pleased after a 11% gain last week that adds to Rezolute, Inc.'s (NASDAQ:RZLT) one-year returns - simplywall.st
Rezolute Inc: chief medical officer Roberts buys $10939 in shares - Investing.com
Rezolute CFO Evans buys $20,250 in company stock - Investing.com
Rezolute director Kim buys shares worth $3.99 million - Investing.com Australia
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Rezolute’s SWOT analysis: ersodetug trials boost stock amid clinical milestones - Investing.com India
Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Two Sigma Investments LP Sells 12,118 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Squarepoint Ops LLC Sells 3,980 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Millennium Management LLC Decreases Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc. - Defense World
Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77% - Yahoo Finance
BTIG maintains $15 target on Rezolute stock following trial update - Investing.com Australia
BTIG maintains $15 target on Rezolute stock following trial update By Investing.com - Investing.com India
Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism - marketscreener.com
Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug - TipRanks
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | - GuruFocus
Rezolute (RZLT) Completes Enrollment for Pivotal sunRIZE Study | RZLT Stock News - GuruFocus
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism - The Manila Times
Man Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - The Globe and Mail
Rezolute, Inc. (RZLT): A Biotech Breakthrough Poised for Explosive Growth - AInvest
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential - MSN
Rezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rezolute Inc (NASDAQ: RZLT) Is The Hottest Stock Right Now. - Stocksregister
Balyasny Asset Management L.P. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
HC Wainwright Analysts Lift Earnings Estimates for Rezolute - Defense World
Wedbush Forecasts Rezolute’s FY2025 Earnings (NASDAQ:RZLT) - Defense World
Rezolute (NASDAQ:RZLT) Earns Outperform Rating from Wedbush - Defense World
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | - GuruFocus
Rezolute (RZLT) to Release Earnings on Wednesday - Defense World
Rezolute Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rezolute (RZLT) Advances Studies on Hyperinsulinism Treatments | RZLT Stock News - GuruFocus
Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment - Nasdaq
Rezolute Secures FDA Breakthrough Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Barclays PLC Takes Position in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com
Rezolute Gets US FDA Breakthrough Therapy Designation for Hypoglycemia Treatment - marketscreener.com
Rezolute (RZLT) Gains FDA Breakthrough Status for Hypoglycemia T - GuruFocus
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):